Mukka Proteins Completes Acquisition of Ento Proteins for INR 32.30 Lakhs
Mukka Proteins Limited has completed the acquisition of the remaining 25.99% equity stake in Ento Proteins Private Limited for a total consideration of INR 32.30 lakhs, effective 23rd February 2026. The transaction involved purchasing 1,000 equity shares and makes Ento Proteins a wholly-owned subsidiary, supporting the company's strategic expansion in alternative proteins business.
*this image is generated using AI for illustrative purposes only.
Mukka Proteins Limited has successfully completed the acquisition of the remaining minority stake in its subsidiary Ento Proteins Private Limited. The transaction, which was announced on 21st February 2026, has been completed with effect from 23rd February 2026, making Ento Proteins a wholly-owned subsidiary.
Acquisition Completion Details
The company has completed the acquisition of 1,000 equity shares of face value Rs. 100 each for a total consideration of Rs. 32,30,000. This transaction follows the Share Purchase Agreement entered into with Holocene Ecosolutions Private Limited, the existing minority shareholder.
| Parameter: | Details |
|---|---|
| Acquisition Stake: | 25.99% equity share capital |
| Total Consideration: | INR 32,30,000 |
| Number of Shares: | 1,000 equity shares |
| Face Value per Share: | Rs. 100 |
| Previous Holding: | 74.01% |
| Current Holding: | 100% |
| Effective Date: | 23rd February 2026 |
Ento Proteins Financial Performance
Ento Proteins Private Limited, which operates as a manufacturer of insect meal and insect oil, has demonstrated consistent growth over the past three years. The subsidiary's financial metrics showcase strong performance in the alternative proteins segment.
| Financial Metrics: | Amount (INR) |
|---|---|
| Authorized Capital: | 10,00,000 |
| Paid-up Capital: | 3,84,700 |
| Turnover (FY 2024-25): | 7,46,27,305 |
| PAT (FY 2024-25): | 49,47,474 |
Historical Revenue Growth
The three-year revenue trajectory of Ento Proteins demonstrates consistent growth in the alternative proteins business segment.
| Year: | Turnover (INR) |
|---|---|
| March 2023: | 4,72,20,140 |
| March 2024: | 6,44,38,907 |
| March 2025: | 7,46,27,305 |
Strategic Investment Rationale
The acquisition aligns with Mukka Proteins' strategic investment plans to expand its alternate proteins business. As disclosed in the regulatory filing, this investment represents a strategic move to consolidate ownership and streamline operations within the subsidiary structure. The transaction was executed on an arm's length basis, with the company clarifying that while Ento Proteins is a related party as a subsidiary, the promoters' interest is limited to their directorship roles.
Regulatory Compliance
The completion disclosure has been made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The share transfer process required no governmental or regulatory approvals and was completed through cash consideration. With this acquisition, the existing Shareholders' Agreement dated 7th September 2021 and its amendments have been rescinded and terminated in their entirety.
Historical Stock Returns for Mukka Proteins
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.45% | -0.91% | -12.20% | -20.90% | -34.23% | -48.21% |
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
